Weight-loss and diabetes drugs such as Ozempic, Wegovy and Zepbound may do more than help patients manage blood sugar and obesity, according to new research led by the Cleveland Clinic.
The study, posted May 21 on the American Society of Clinical Oncology website, found that people taking GLP-1 drugs were less likely to see certain obesity-related cancers spread, including lung, breast, colorectal and liver cancers.
Researchers said the findings add to a growing body of evidence suggesting GLP-1 drugs may have anti-inflammatory and anti-tumor effects beyond their role in diabetes and weight management. The research has not yet been published in a peer-reviewed journal, and experts cautioned that the study was observational, meaning it cannot prove the drugs directly slowed cancer progression.
Read Full Article Here
